Acute and Clinically Relevant Drug-induced Liver Injury: a Population Based Case-control Study

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2004 Jun 23

PMID 15206996

Citations 125

Authors

Francisco J de Abajo

Dolores Montero

Mariano Madurga

Luis A Garcia Rodriguez

Affiliations

Soon will be listed here.

Abstract

Aims: To provide quantitative information about the absolute and relative risks of acute and clinically relevant drug-induced liver injury.

Methods: We performed a population-based case-control study using the UK-based General Practice Research Database as the source of information. A total of 1,636,792 persons subjects aged 5-75 years old registered in the database from 1 January, 1994 to 31 December, 1999 were followed-up for a total of 5,404,705 person-years. Cases were identified by an exhaustive computer search, then reviewed manually and finally validated against the clinical records. Only idiopathic cases serious enough to be referred to hospital or a consultant were selected. A total of 5000 controls were randomly sampled from the person-time of study cohort. Current users were defined if a prescription ended within 15 days of the index date, and nonusers if there was no prescription before the index date.

Results: One hundred and twenty-eight patients were considered as valid cases, being the crude incidence rate of 2.4 (95% confidence interval: 2.0, 2.8) per 100 000 person-years. The strongest associations were found with chlorpromazine (adjusted odds ratio (AOR); 95% CI = 416; 45, 3840), amoxicillin/clavulanic acid (AOR = 94.8; 27.8, 323), flucloxacillin (AOR = 17.7; 4.4, 71.0), macrolides (AOR = 6.9; 2.3, 21.0), tetracyclines (AOR = 6.2; 2.4, 15.8); metoclopramide (AOR = 6.2; 1.8, 21.3); chlorpheniramine (AOR = 9.6; 1.9, 49.7); betahistine (AOR = 15.3; 2.9, 80.7); sulphasalazine (AOR = 25.5; 6.0, 109); azathioprine (AOR = 10.5; 1.4, 76.4), diclofenac (AOR = 4.1; 1.9, 8.8) and antiepileptics (AOR = 5.1; 1.9, 13.7). A dose-effect was apparent for diclofenac, amoxicillin/clavulanic acid and flucloxacillin. The combination of two or more hepatotoxic drugs increased the risk by a factor of 6. The highest crude incidence rates were found for chlorpromazine, azathioprine, and sulfasalazine (about 1 per 1000 users).

Conclusions: Idiopathic, acute and clinically relevant liver injury, which has the use of drugs as the most probable aetiology, is a rare event in the general population. The relative risks of 40 drugs/therapeutic classes are provided, along with the crude incidence rates for 15 of them where a statistical association was found.

Citing Articles

Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.

Maris B, Grama A, Pop T Int J Mol Sci. 2025; 26(5).

PMID: 40076629 PMC: 11901067. DOI: 10.3390/ijms26052006.

The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients.

Bjornsson R, Sigurdsson S, Arnarson D, Logason E, Bjornsson E Drug Saf. 2025; .

PMID: 40072769 DOI: 10.1007/s40264-025-01541-w.

Liver diseases: epidemiology, causes, trends and predictions.

Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z Signal Transduct Target Ther. 2025; 10(1):33.

PMID: 39904973 PMC: 11794951. DOI: 10.1038/s41392-024-02072-z.

Clinical Practice Guidelines for Topical NSAIDs in the Treatment of Sports Injuries.

Xiong Y, Liu Y, Zhou J, Shang X, He H, Hongchen H J Evid Based Med. 2025; 18(1):e12661.

PMID: 39791352 PMC: 11822085. DOI: 10.1111/jebm.12661.

Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on Roussel Uclaf Causality Assessment Method and HLA B*57:01 Genotype: From Metabolic CYP 3A4/3A7 to Immune Mechanisms.

Teschke R Biomedicines. 2024; 12(10).

PMID: 39457521 PMC: 11504411. DOI: 10.3390/biomedicines12102208.

References

ODonohue J, Oien K, Donaldson P, Underhill J, Clare M, MacSween R . Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000; 47(5):717-20. PMC: 1728095. DOI: 10.1136/gut.47.5.717. View

Garcia Rodriguez L, Perez Gutthann S . Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45(5):419-25. PMC: 1873548. DOI: 10.1046/j.1365-2125.1998.00701.x. View

Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C . Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36(2):451-5. DOI: 10.1053/jhep.2002.34857. View

Ibanez L, Perez E, Vidal X, Laporte J . Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002; 37(5):592-600. DOI: 10.1016/s0168-8278(02)00231-3. View

Meier C, Krahenbuhl S, Schlienger R, Jick H . Association between body mass index and liver disorders: an epidemiological study. J Hepatol. 2002; 37(6):741-7. DOI: 10.1016/s0168-8278(02)00298-2. View

Spigset O, Hagg S, Bate A . Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol. 2003; 18(3):157-61. DOI: 10.1097/01.yic.0000066455.73432.d2. View

Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M . Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003; 327(7405):18-22. PMC: 164233. DOI: 10.1136/bmj.327.7405.18. View

Benichou C . Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2):272-6. DOI: 10.1016/0168-8278(90)90124-a. View

Friis H, ANDREASEN P . Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med. 1992; 232(2):133-8. DOI: 10.1111/j.1365-2796.1992.tb00562.x. View

10.

Derby L, Jick H, Henry D, Dean A . Cholestatic hepatitis associated with flucloxacillin. Med J Aust. 1993; 158(9):596-600. DOI: 10.5694/j.1326-5377.1993.tb137624.x. View

11.

Derby L, Gutthann S, Jick H, Dean A . Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy. 1993; 13(4):353-8. View

12.

Perez Gutthann S, Garcia Rodriguez L . The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology. 1993; 4(6):496-501. View

13.

Garcia Rodriguez L, Williams R, Derby L, Dean A, Jick H . Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994; 154(3):311-6. DOI: 10.1001/archinte.1994.00420030117012. View

14.

Bakke O, Manocchia M, de Abajo F, Kaitin K, Lasagna L . Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995; 58(1):108-17. DOI: 10.1016/0009-9236(95)90078-0. View

15.

Garcia Rodriguez L, Stricker B, ZIMMERMAN H . Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996; 156(12):1327-32. DOI: 10.1001/archinte.1996.00440110099013. View

16.

Sarfraz A, Cook M . Sulpiride-induced cholestalic jaundice. Aust N Z J Psychiatry. 1996; 30(5):701-2. DOI: 10.3109/00048679609062671. View

17.

Garcia Rodriguez L, Ruigomez A, Jick H . A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy. 1997; 17(4):721-8. View

18.

Christopher K, Hyatt P, Horkan C, Yodice P . Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol. 2002; 97(2):489-90. DOI: 10.1111/j.1572-0241.2002.05505.x. View